These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31481310)

  • 1. Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions.
    Li Z; Chen G; Ding L; Wang Y; Zhu C; Wang K; Li J; Sun M; Oupicky D
    Mol Ther; 2019 Dec; 27(12):2100-2110. PubMed ID: 31481310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
    Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
    ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
    Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
    Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice.
    Dai L; Cheng L; Zhang X; Jiang Q; Zhang S; Wang S; Li Y; Chen X; DU T; Yang Y; Tian H; Fan P; Yan N; Dai L; Wei Y; Deng H
    Neoplasma; 2011; 58(6):538-47. PubMed ID: 21895408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
    Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
    Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
    Taniguchi H; Natori Y; Miyagi Y; Hayashi K; Nagamura F; Kataoka K; Imai K
    Int J Cancer; 2021 Aug; 149(3):646-656. PubMed ID: 33783816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
    Su WP; Cheng FY; Shieh DB; Yeh CS; Su WC
    Int J Nanomedicine; 2012; 7():4269-83. PubMed ID: 22904633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
    Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
    Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
    Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
    Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.
    Wani N; Nasser MW; Ahirwar DK; Zhao H; Miao Z; Shilo K; Ganju RK
    Breast Cancer Res; 2014 May; 16(3):R54. PubMed ID: 24886617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
    Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
    Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.
    Jung MJ; Rho JK; Kim YM; Jung JE; Jin YB; Ko YG; Lee JS; Lee SJ; Lee JC; Park MJ
    Oncogene; 2013 Jan; 32(2):209-21. PubMed ID: 22370645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perfluorocarbon Nanoemulsions Enhance Therapeutic siRNA Delivery in the Treatment of Pulmonary Fibrosis.
    Ding L; Tang S; Tang W; Mosley DD; Yu A; Sil D; Romanova S; Bailey KL; Knoell DL; Wyatt TA; Oupický D
    Adv Sci (Weinh); 2022 Mar; 9(8):e2103676. PubMed ID: 34994102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression.
    Masjedi A; Ahmadi A; Atyabi F; Farhadi S; Irandoust M; Khazaei-Poul Y; Ghasemi Chaleshtari M; Edalati Fathabad M; Baghaei M; Haghnavaz N; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Sabz G; Hasanzadeh S; Jadidi-Niaragh F
    Int J Biol Macromol; 2020 Apr; 149():487-500. PubMed ID: 32004600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemokine receptor CXCR4 gene silencing with shRNA inhibits breast cancer metastasis to the lung in nude mice].
    Zhang MX; Han N; Yu SY; Leng Y
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):325-9. PubMed ID: 18953828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
    Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
    J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.
    Bjorge JD; Pang AS; Funnell M; Chen KY; Diaz R; Magliocco AM; Fujita DJ
    PLoS One; 2011 Apr; 6(4):e19309. PubMed ID: 21541295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
    Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
    Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition.
    Lee HJ; Seo NJ; Jeong SJ; Park Y; Jung DB; Koh W; Lee HJ; Lee EO; Ahn KS; Ahn KS; Lü J; Kim SH
    Carcinogenesis; 2011 Jun; 32(6):804-11. PubMed ID: 21289371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
    Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
    Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.